Luye Pharma
Luye Pharma Group Ltd., commonly referred to as Luye Pharma, is a prominent biopharmaceutical company headquartered in China (CN). Established in 1997, the company has made significant strides in the pharmaceutical industry, focusing on innovative drug development and manufacturing. With a strong presence in major operational regions including Asia, Europe, and North America, Luye Pharma is dedicated to addressing unmet medical needs across various therapeutic areas. The company’s core products encompass a range of advanced formulations, particularly in oncology, central nervous system disorders, and cardiovascular diseases. Luye Pharma is recognised for its unique drug delivery systems, which enhance the efficacy and patient compliance of its therapies. With a commitment to research and development, Luye Pharma has achieved notable milestones, positioning itself as a key player in the global biopharmaceutical market.
DitchCarbon Score
How does Luye Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Luye Pharma's score of 19 is lower than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Luye Pharma's reported carbon emissions
In 2022, Luye Pharma reported total carbon emissions of approximately 78,081,450 kg CO2e. This figure includes Scope 1 emissions of about 2,341,110 kg CO2e from fugitive emissions and 75,960 kg CO2e from mobile combustion. Additionally, Scope 2 emissions accounted for approximately 48,278,890 kg CO2e from purchased electricity and 18,980,050 kg CO2e from purchased steam. The company's emissions have shown a trend of increase over the years, with total emissions rising from about 68,537,500 kg CO2e in 2021 and 72,087,050 kg CO2e in 2020. Notably, Luye Pharma has not disclosed any Scope 3 emissions data, which typically includes indirect emissions from the supply chain and product use. Despite the lack of specific reduction targets or initiatives, Luye Pharma has committed to transparency in its emissions reporting. The company does not currently have any science-based targets (SBTi) or documented reduction initiatives. All emissions data is sourced directly from Luye Pharma Group Ltd., with no cascaded data from parent or related organizations. Overall, while Luye Pharma has made strides in emissions disclosure, the absence of reduction commitments highlights an area for potential improvement in their climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Scope 1 | 2,284,540 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | - | - | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Luye Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
